HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG. MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000 RECENT MAJOR CHANGES
INDICATIONS AND USAGEMYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSFor Injection: 4.5 mg as a lyophilized cake or powder in a single-dose vial for reconstitution and dilution (3). CONTRAINDICATIONSHypersensitivity to MYLOTARG or any of its components (4). WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions (greater than 15%) were hemorrhage, infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash, mucositis, febrile neutropenia, and decreased appetite (6). To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION. Revised: 8/2021 |
HIGHLIGHTS OF PRESCRIBING INFORMATIONThese highlights do not include all the information needed to use MYLOTARG safely and effectively. See full prescribing information for MYLOTARG. MYLOTARG™ (gemtuzumab ozogamicin) for injection, for intravenous use Initial U.S. Approval: 2000 RECENT MAJOR CHANGES
INDICATIONS AND USAGEMYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: DOSAGE AND ADMINISTRATION
DOSAGE FORMS AND STRENGTHSFor Injection: 4.5 mg as a lyophilized cake or powder in a single-dose vial for reconstitution and dilution (3). CONTRAINDICATIONSHypersensitivity to MYLOTARG or any of its components (4). WARNINGS AND PRECAUTIONS
ADVERSE REACTIONSThe most common adverse reactions (greater than 15%) were hemorrhage, infection, fever, nausea, vomiting, constipation, headache, increased AST, increased ALT, rash, mucositis, febrile neutropenia, and decreased appetite (6). To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. See 17 for PATIENT COUNSELING INFORMATION. Revised: 8/2021 |
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.